Publication | Open Access

Discovery of N -(5-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-4-methoxy-2-(4-methyl-1,4-diazepan-1-yl)phenyl)acrylamide (CHMFL-ALK/EGFR-050) as a potent ALK/EGFR dual kinase inhibitor capable of overcoming a variety of ALK/EGFR associated drug resistant mutants in NSCLC

Drug TargetMedicineRational Drug DesignPharmacotherapyAnti-cancer AgentDrug DevelopmentPharmacologyBiomolecular EngineeringDrug DiscoveryDrug Resistance